查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464946

阿維莫泮市場：按治療應用、最終用戶分類 - 2024-2030 年全球預測

Alvimopan Market by Therapeutic Application (Opioid-Induced Constipation, Postoperative Ileus Prevention), End-User (Hospitals, Surgical Centers) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年阿維莫泮市場規模為62億美元，預計2024年將達65.1億美元，2030年將達到88.7億美元，複合年成長率為5.23%。

阿維莫泮是一種醫學化合物，被歸類為週邊作用的福西鴉片受體拮抗。阿維莫泮是專門為抵消鴉片類藥物對腸道的副作用而設計的，因此它可以幫助控制術後腸梗阻，即腹部手術後腸道暫時麻痺和正常腸道功能被破壞的情況。外科手術，尤其是腹部手術的興起，直接導致對阿維莫泮等術後護理解決方案的需求增加。對鴉片類藥物引起的併發症的認知和管理策略的提高進一步增加了對阿維莫泮等有效藥物的需求。醫療保健設施的改善、住院時間的縮短和醫療成本的降低正在推動阿維莫泮在臨床實踐中的採用。然而，嚴格的監管和漫長的核准程序可能會延遲阿維莫泮的市場進入。阿維莫泮存在副作用風險，這可能會對醫療保健提供者和患者的採用造成挑戰。此外，新興經濟體發展醫療基礎設施和增加外科手術也帶來了巨大的成長機會。與醫療機構和保險公司合作，強調使用阿維莫泮的成本效益可能會創造市場成長潛力。

主要市場統計
基準年[2023] 62億美元
預測年份 [2024] 65.1億美元
預測年份 [2030] 88.7億美元
複合年成長率（%） 5.23%

治療用途：緩解鴉片類藥物引起的便秘的多種應用

阿維莫泮用於治療鴉片類藥物引起的便秘 (OIC)，透過抑制鴉片類藥物對腸道的作用，在不影響疼痛管理功效的情況下緩解便秘。當第一線瀉藥無效時，阿維莫泮是治療鴉片類藥物患者便秘症狀的重要選擇。阿維莫泮適用於 POI 預防，這是一種積極的方法，可以加快胃腸道恢復並降低住院費用。阿維莫泮通常用於接受選擇性腸切除手術的成年患者。

最終使用者：外科中心越來越偏好使用阿維莫泮治療術後腸阻塞

在醫院，阿維莫泮主要用於加速手術後的恢復，尤其是胃腸道手術後的恢復。阿維莫泮的需求是縮短住院時間並降低術後腸阻塞（POI）的發生率。手術中心使用阿維莫泮幫助患者在腹部手術後康復。阿維莫泮在預防 POI 方面的作用對於外科中心維持關鍵效率和病患滿意度指標特別有價值。

區域洞察

在美洲，美國和加拿大處於阿維莫泮市場的前沿，這主要是由於 FDA 的核准並被許多醫院採納為術後護理方案。高額醫療支出、先進醫療設施的廣泛普及以及持續的研究是阿維莫泮在該地區使用的主要原因。歐盟對阿維莫泮的採用情況因國家而異，取決於國家醫療保健系統政策、報銷方式以及術後護理創新意識。阿維莫泮的認知和使用正在逐漸擴大，特別是在衛生系統強大的波灣合作理事會(GCC) 國家。在亞太地區，由於外科手術的增加和醫療保健行業的擴張，中國對阿維莫泮的需求不斷成長。最近的專利和研究引起了人們對阿維莫泮的興趣增加，特別是在日本，預計它可以有效加速老年人的術後復原。印度的阿維莫泮市場仍處於起步階段，醫療基礎設施有所改善，術後護理意識有所提高。

FPNV定位矩陣

FPNV定位矩陣對於評估Alvimopan市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對 Alvimopan 市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1. Alvimopan 市場規模及預測為何？

2.Alvimopan 市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3. Alvimopan市場的技術趨勢和法規結構是什麼？

4.Alvimopan市場主要廠商的市場佔有率是多少？

5.進入Alvimopan市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 增加手術干預，包括腹部手術
      • 提高對鴉片類藥物引起的併發症的認知和管理策略
      • 改善世界各地的醫療保健設施
    • 抑制因素
      • 法規嚴格、核准流程長
    • 機會
      • 探索阿維莫泮治療應用的研發舉措
      • 增加對公共和私人醫療基礎設施的投資
    • 任務
      • 與阿維莫泮相關的副作用風險
  • 市場區隔分析
    • 治療應用：緩解鴉片類藥物引起的便秘的多種應用
    • 最終使用者：阿維莫泮在手術中心越來越受歡迎，用於治療術後腸阻塞
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 依治療用途分類的阿維莫泮市場

  • 鴉片類藥物引起的便秘
  • 術後腸阻塞的預防

第7章 Alvimopan 市場：依最終用戶分類

  • 醫院
  • 手術中心

第8章 南北美洲阿維莫泮市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章 Alvi Mopan亞太區市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲阿維莫泮市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Hikma Pharmaceuticals 在美國推出促進腸胃恢復的阿維莫泮膠囊
  • 戰略分析和建議

第12章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-151228454438

[189 Pages Report] The Alvimopan Market size was estimated at USD 6.20 billion in 2023 and expected to reach USD 6.51 billion in 2024, at a CAGR 5.23% to reach USD 8.87 billion by 2030.

Alvimopan is a medical compound categorized under the umbrella of peripherally acting μ-opioid receptor antagonists. Alvimopan is specifically designed to counteract the side effects of opioids on the bowel, thus aiding in the management of postoperative ileus, a condition where the bowel becomes temporarily paralyzed after abdominal surgery, inhibiting normal bowel functions. The global rise in surgical interventions, especially abdominal surgeries, directly correlates with the increasing demand for postoperative care solutions such as Alvimopan. Growing awareness and management strategies for opioid-induced complications further elevate the need for effective medications such as Alvimopan. Improved healthcare facilities and an emphasis on reducing hospital stays and healthcare costs propel the adoption of Alvimopan in clinical settings. However, strict regulations and long approval processes may delay market access for Alvimopan. Alvimopan carries the risk of side effects, which may create challenges for adoption among healthcare providers and patients. Moreover, developing healthcare infrastructure and increasing surgical procedures in emerging economies present significant growth opportunities. Collaborating with healthcare facilities and insurers to highlight the cost-effectiveness of using Alvimopan may create growth potential in the market.

KEY MARKET STATISTICS
Base Year [2023] USD 6.20 billion
Estimated Year [2024] USD 6.51 billion
Forecast Year [2030] USD 8.87 billion
CAGR (%) 5.23%

Therapeutic Application: Diverse scope of applications for easing opioid-Induced constipation

Alvimopan is used in opioid-induced constipation (OIC) by blocking the opioid effects on the gut, thus easing constipation without compromising pain management efficacy. Alvimopan serves as a crucial option for managing constipation symptoms in opioid-treated patients, in failure of first-line laxatives. Alvimopan is preferred for preventing POI, a proactive approach, allowing for faster gastrointestinal recovery and reduced hospitalization costs. Alvimopan is typically reserved for adult patients, undergoing elective bowel resection surgery.

End-User: Increasing preference for alvimopan in surgical centers for treating postoperative ileus

In hospitals, Alvimopan is predominantly used to enhance postoperative recovery, particularly after surgeries involving the gastrointestinal tract. The need for Alvimopan in these settings is driven by its ability to reduce length of hospital stays and lower the rates of postoperative ileus (POI). Surgical centers use Alvimopan to aid in the recovery of patients undergoing abdominal surgeries. Alvimopan's role in preventing POI is particularly valuable in maintaining the efficiency and patient satisfaction metrics critical to the surgical centers.

Regional Insights

In the Americas region, the U.S. and Canada are at the forefront in the Alvimopan market, largely due to FDA approval and its inclusion in postoperative care protocols in numerous hospitals. High healthcare spending, widespread availability of advanced medical facilities, and ongoing research contribute to its substantial use in the region. Alvimopan's adoption in the European Union varies by country, depending on national healthcare systems' policies, reimbursement practices, and the extent of awareness about postoperative care innovations. The awareness and use of Alvimopan are gradually growing, particularly in Gulf Cooperation Council (GCC) countries with robust healthcare systems. In the APAC region, the demand for Alvimopan in China is growing, driven by increasing surgical procedures and an expanding healthcare sector. Recent patents and research have stirred interest in Alvimopan, especially for its potential benefits in enhancing postoperative recovery in the elderly population, which is significant in Japan. The market for Alvimopan in India is nascent, given the rising healthcare infrastructure and increasing awareness about postoperative care.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alvimopan Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alvimopan Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alvimopan Market, highlighting leading vendors and their innovative profiles. These include Adolor Corporation, Adooq Bioscience LLC, Hikma Pharmaceuticals PLC, Manus Aktteva Biopharma LLP, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Alvimopan Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Therapeutic Application
    • Opioid-Induced Constipation
    • Postoperative Ileus Prevention
  • End-User
    • Hospitals
    • Surgical Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Alvimopan Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alvimopan Market?

3. What are the technology trends and regulatory frameworks in the Alvimopan Market?

4. What is the market share of the leading vendors in the Alvimopan Market?

5. Which modes and strategic moves are suitable for entering the Alvimopan Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in surgical interventions including abdominal surgeries
      • 5.1.1.2. Growing awareness and management strategies for opioid-induced complications
      • 5.1.1.3. Improved healthcare facilities worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulations and long approval processes
    • 5.1.3. Opportunities
      • 5.1.3.1. R&D initiatives for exploring therapeutic applications of alvimopan
      • 5.1.3.2. Increasing investments in public and private healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Risk of associated side effects of alvimopan
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapeutic Application: Diverse scope of applications for easing opioid-Induced constipation
    • 5.2.2. End-User: Increasing preference for alvimopan in surgical centers for treating postoperative ileus
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Alvimopan Market, by Therapeutic Application

  • 6.1. Introduction
  • 6.2. Opioid-Induced Constipation
  • 6.3. Postoperative Ileus Prevention

7. Alvimopan Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Surgical Centers

8. Americas Alvimopan Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Alvimopan Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Alvimopan Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Hikma Pharmaceuticals Launches Alvimopan Capsules for Enhanced Gastrointestinal Recovery in the US
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ALVIMOPAN MARKET RESEARCH PROCESS
  • FIGURE 2. ALVIMOPAN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALVIMOPAN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ALVIMOPAN MARKET DYNAMICS
  • FIGURE 7. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ALVIMOPAN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. ALVIMOPAN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALVIMOPAN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALVIMOPAN MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ALVIMOPAN MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALVIMOPAN MARKET SIZE, BY OPIOID-INDUCED CONSTIPATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ALVIMOPAN MARKET SIZE, BY OPIOID-INDUCED CONSTIPATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALVIMOPAN MARKET SIZE, BY POSTOPERATIVE ILEUS PREVENTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ALVIMOPAN MARKET SIZE, BY POSTOPERATIVE ILEUS PREVENTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALVIMOPAN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ALVIMOPAN MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALVIMOPAN MARKET SIZE, BY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ALVIMOPAN MARKET SIZE, BY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. AMERICAS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 20. AMERICAS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 21. AMERICAS ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 22. AMERICAS ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 23. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 24. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 26. ARGENTINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 28. ARGENTINA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 29. BRAZIL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 30. BRAZIL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 31. BRAZIL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 32. BRAZIL ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 33. CANADA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 34. CANADA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 35. CANADA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 36. CANADA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 37. MEXICO ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 38. MEXICO ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 39. MEXICO ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 40. MEXICO ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 41. UNITED STATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 42. UNITED STATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 44. UNITED STATES ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 46. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 54. AUSTRALIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. AUSTRALIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. CHINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 58. CHINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 59. CHINA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 60. CHINA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 61. INDIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 62. INDIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 63. INDIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 64. INDIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 65. INDONESIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 66. INDONESIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 67. INDONESIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. INDONESIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. JAPAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 70. JAPAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 71. JAPAN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 72. JAPAN ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. MALAYSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 76. MALAYSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 78. PHILIPPINES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 80. PHILIPPINES ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. SINGAPORE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 84. SINGAPORE ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. TAIWAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. TAIWAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. TAIWAN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 92. TAIWAN ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 93. THAILAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 94. THAILAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 95. THAILAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 96. THAILAND ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 97. VIETNAM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. VIETNAM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. VIETNAM ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 100. VIETNAM ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 107. DENMARK ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. DENMARK ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. DENMARK ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 110. DENMARK ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 111. EGYPT ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. EGYPT ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. EGYPT ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 114. EGYPT ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 115. FINLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. FINLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. FINLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. FINLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. FRANCE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. FRANCE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. FRANCE ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 122. FRANCE ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 123. GERMANY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. GERMANY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. GERMANY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. GERMANY ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. ISRAEL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. ISRAEL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. ISRAEL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 130. ISRAEL ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 131. ITALY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. ITALY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. ITALY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 134. ITALY ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 136. NETHERLANDS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. NETHERLANDS ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. NIGERIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. NIGERIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. NIGERIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. NIGERIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. NORWAY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. NORWAY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. NORWAY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 146. NORWAY ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 147. POLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. POLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. POLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 150. POLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 151. QATAR ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. QATAR ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. QATAR ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 154. QATAR ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 155. RUSSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. RUSSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. RUSSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 158. RUSSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. SPAIN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 168. SPAIN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 169. SPAIN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 170. SPAIN ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 171. SWEDEN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. SWEDEN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SWEDEN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. SWEDEN ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. SWITZERLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 178. SWITZERLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 179. TURKEY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. TURKEY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. TURKEY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. TURKEY ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 191. ALVIMOPAN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. ALVIMOPAN MARKET, FPNV POSITIONING MATRIX, 2023